D2M BIOTHERAPEUTICS
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. The company is a tumor immunological drug developer that aims to expand the potential of immunotherapy.
D2M BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-01-01
Address:
Grand Cayman, Midland, Cayman Islands
Country:
Cayman Islands
Total Employee:
101+
Status:
Active
Contact:
(617)586-5012
Total Funding:
10 M USD
Similar Organizations
RJH Biosciences
RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids.
Reservoir Neuroscience
Reservoir Neuroscience is a biopharma company that develops novel therapeutics.
Refuge Biotechnologies
Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Rafael Holdings
Rafael Holdings is a company focused on the development of novel cancer therapies.
Nivien Therapeutics
Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
NKGen Biotech
NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.
Nanocan Therapeutics
Nanocan Therapeutics provides medicines and other products intended to patients with certain cancers, respiratory tract infections.
NonExomics
NonExomics develops therapeutics to diagnose and cure diseases emanating from the nonexome.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Pragma Bio
Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune diseases.
Mutabilis
Mutabilis is discovery of new therapeutic targets for the development of anti-infectives.
MiniVax
MiniVax is focused on the development of solutions for the treatment and prevention of opportunistic infections.
Magnetic Insight
MPI enables best in class cellular imaging to measure the efficacy of cancer immunotherapies.
20n Bio
20n Bio is a VC-backed start-up dedicated to the computational design of novel protein therapeutics.
Advent Therapeutics
Advent Therapeutics is focused on providing therapies for micro-orphan applications.
Aleta Biotherapeutics
Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.
Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Auron Therapeutics
Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
AgeX Therapeutics
AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases.
Adaptate Biotherapeutics
Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ.
Antera Therapeutics
Antera Therapeutics is creating therapies that will prevent allergy development in children.
AffyXell Therapeutics
AffyXell Therapeutics develops novel mesenchymal stem cell therapies.
Advanced Proteome Therapeutics
Advanced Proteome Therapeutics is focused on the development of novel therapeutics for the treatment of cancerous tumors.
Exalys Therapeutics
Exalys Therapeutics is focused on the development of first-in-class therapies for the treatment of inflammatory disorders.
Elektrofi
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.
Endlyz Therapeutics
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.
BEAT BioTherapeutics
BEAT BioTherapeutics develops novel therapies for heart diseases.
BIMINI Biotech
BIMINI Biotech is a startup that develops innovative therapeutic strategies for oncology.
Bedrock Therapeutics
Bedrock Therapeutics is an AAV research and Development Gene Therapy Company.
Fresh Wind Biotechnologies USA
Biotechnologies, Therapeutics, Multi-omics, Bioinformatics
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
FIRE1
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Fuse Biotherapeutics
Fuse Biotherapeutics is a biotech company developing next-generation immune-modulating therapeutics for patients with cancers.
Trilo Therapeutics
Trilo Therapeutics is developing best-in-class peptide-drug conjugates that address the dose-limiting toxicity of current generation ADCs.
Tacalyx
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA
Talus Bio
Talus Bio is a drug discovery biotech startup working on drug development for gene regulators.
Tallac Therapeutics
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tizona Therapeutics
Tizona develops next-generation immunotherapies
Tabomedex Biosciences, Inc.
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes.
Juventas
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
4D Pharma
4D Pharma PLC is a world leader in the development of live biotherapeutics.
KinaRx
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia.
Serenity Bioworks
Developing therapeutics derived from cellular stress pathways.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Sarentis Therapeutics
Sarentis Therapeutics engages in the development of therapeutics for the treatment of pain.
Synthekine
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
DMD Therapeutics
DMD Therapeutics intends to use the funds to move DMD-813 into drug development for the treatment of Duchenne Muscular Dystrophy.
Dianomi Therapeutics
Dianomi Therapeutics company focused on developing treatments for inflammatory diseases, initially targeting osteoarthritis (OA).
Dopavision
Dopavision is a therapeutic company developing a digital therapeutic for myopia.
Deciduous Therapeutics
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies.
HbO2 Therapeutics
HbO2 Therapeutics develops and manufactures oxygen carrying solutions.
Hummingbird Bioscience
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Horizon Pharma
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
ITabMed
ITabMed's aim of "Innovating for Life" continues, with a focus on the discovery and development of cancer immunotherapy treatments.
IOmx Therapeutics
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics.
iCo Therapeutics
ICo Therapeutics is focused on the research and development of drug delivery technologies.
Inimmune
Inimmune is focused on the discovery and development of novel immunotherapeutics for an array of disease areas.
IntraOp Medical
IntraOp® is the leader in Electron Therapy
IMTherapeutics
IM Therapeutics develops personalized immuno-therapeutic drugs.
ImmuneOnco Biopharma
ImmuneOnco is a tumor immunotherapy product developer engaged in the development and research of tumor immunotherapy products.
GeneQuantum Healthcare
GeneQuantum Healthcare is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.
Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Gemstone Biotherapeutics
Gemstone Biotherapeutics is a pre-clinical research and development initiative.
Cyprium Therapeutics
Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Corvidia
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
COARE Biotechnology
COARE Biotechnology is focused on developing treatments for tumor-initiating cells in solid tumor cancers.
Conatus Pharmaceuticals
Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.
Palvella Therapeutics
Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.
PrIME Biologics
PrIME Biologics Pte Limited develops a disposable procedure
ProThera Biologics
ProThera Biologics focuses on unmet medical needs by developing integrated theranostic and therapeutic biomolecules.
ProLynx
ProLynx technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs.
YourChoice Therapeutics
YourChoice Therapeutics is revolutionizing contraceptives for men and women by developing novel non-hormonal contraceptive products.
Current Employees Featured
Founder
Investors List
Apricot Capital
Apricot Capital investment in Seed Round - D2M Biotherapeutics
More informations about "D2M Biotherapeutics"
About D2M Bio - Global Leader in Drug Target …
D2M is uniquely positioned to overcome the challenge of transforming Genome-Wide Association Studies into disease-causing genes. Our genetic-centric, multi-omics, data-driven platform enables us to consistently develop a broad set of …See details»
D2M Biotherapeutics - Crunchbase Company Profile & Funding
Organization. D2M Biotherapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. D2M Biotherapeutics focuses on the development …See details»
D2M Biotherapeutics Ltd. - Drug pipelines, Patents, Clinical
About D2M Biotherapeutics, Inc. D2M Biotherapeutics is a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines to help patients with …See details»
Identifying Genetically Validated Targets - D2M …
At D2M, we leverage Genome Wide Association Studies (GWAS) along with emerging multi-functional omics data, gaining insights into novel therapeutic targets. Furthermore, we employ systemic Mendelian Randomization …See details»
D2M Biotherapeutics - LinkedIn
D2M Biotherapeutics is a startup biotech company located at Natick, MA. D2M (Data to Medicine) is a human-genetics driven biotherapeutics discovery company with a focus on immuno-oncology and ...See details»
D2M Biotherapeutics Company Profile 2024: Valuation, Funding ...
D2M Biotherapeutics General Information Description. Developer of macromolecule drug designed for tumor immunity. The company aims to use modern genetics to develop more …See details»
D2M Biotherapeutics - Funding, Financials, Valuation & Investors
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
/C O R R E C T I O N -- D2M Biotherapeutics, Inc./ - Yahoo Finance
Apr 18, 2024 D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory diseases and cancers, …See details»
D2M Biotherapeutics - Updates, News, Events, Signals & Triggers
D2M Biotherapeutics may be growing as the company has announced the first patient dosed in a Phase 1 trial for one of its novel immunotherapeutics. This milestone suggests progress in the …See details»
Our Team - D2M Biotherapeutics
Dr. Zhang's is the Co-founder and Chief Scientific Officer at D2M Biotherapeutics. Trained as an immunologist, Dr. Zhang has 20 years of drug discovery & development experience in cancer immunotherapy. Before co-founding D2M, …See details»
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 …
D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory diseases and cancers, today …See details»
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 …
Apr 18, 2024 D2M Biotherapeutics have shown that DM919 prevents MICA/B shedding, stabilizes surface MICA/B and presents shed MICA/B to activate NKG2D on NK or T cells and …See details»
Our Pipeline - D2M Biotherapeutics
D2M Biotherapeutics have shown that DM919 prevents MICA/B shedding, stabilizes surface MICA/B, presents shed MICA/B to activate NKG2D on NK or T cells, and enhances NK and T …See details»
Series A - D2M Biotherapeutics - 2022-12-26 - Crunchbase
Dec 26, 2022 Organization Name . D2M Biotherapeutics . Announced Date Dec 26, 2022; Closed On Date Dec 26, 2022; Funding Type Series A; Funding Stage Early Stage Venture; …See details»
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 …
NATICK, Mass., April 18, 2024 /PRNewswire/ -- D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological …See details»
DM919 Receives FDA Clearance of IND Application ... - D2M …
Natick, Mass., December 21, 2023 — D2M Biotherapeutics, Inc. (D2M), an immune therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared …See details»
Latest News & Insights | D2M Biotherapeutics
Natick, Mass., April 19, 2024 -- D2M Biotherapeutics, Inc. (D2M),... Read More. Press Releases. D2M Biotherapeutics DM919 Investigational New Drug Application Approved by China’s …See details»
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 …
Apr 25, 2024 NATICK, Mass., April 18, 2024 /PRNewswire/ — D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating …See details»
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 …
NATICK, MA, USA I April 18, 2024 I D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory …See details»